冠心病患者的当今降脂治疗
摘要
近10 a来,几个大型随机临床试验已确立降低低密度脂蛋白胆固醇(LDL-C)是预防冠心病的关键因素[1].最有效的降脂药物是3羟基3甲基戊二酰辅酶A(HMG-CoA)还原酶抑制剂,更普通地称为他汀类药物.现已明确,他汀类药物可以降低冠心病的发病率和病死率,其最大益处是高危冠心病患者的绝对危险降低.本文就冠心病高危患者的当今降脂治疗观点进行综述.
出处
《临床医药实践》
2003年第10期725-727,共3页
Proceeding of Clinical Medicine
参考文献24
-
1Stein EA,Chio C. Management of dislipidemia in the high risk patient[J]. Am Heart J,2002, 144(Suppl): 543-550.
-
2Jacobson TA ,Schein JR,Williamson A et al. Maximizing the cost-effectiveness of lipid-lowering therapy [J]. Arch intern Med, 1998,158:1977- 1989.
-
3Scandinavian Simuastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease:the candinavian. Simvastatin Survival Study(4s)[J]. Lancet . 1994,344 : 1383-1389.
-
4Downs JR ,Clearfield M ,Weis Set al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels:results of AFCAPS/TexCAPS [J]. JAMA, 1998, 279:1615-1622.
-
5Expert Panel on Detection,Evaluation and Treatment of a High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program(NCEP) Expert Panel on Detection, Evaluation,and Treatment of High Blood Cholesterol on Adults (Adult,Treatment Panel Ⅱ )[J]. JAMA, 2001 . 285,2486- 2497.
-
6American Diabetes Association. Management of dyslipidemia in adults with diabetes [J]. Diabetes Care, 2002,25(1 suppl) :s74-s77.
-
7Second Joint Task Force of European and other Societies on Coronary Prevention. Prevention of coronary heart disease in clinical practice., recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention [J]. Eur Heart J,1998,19:1434-1503.
-
8Pearson TA ,Laurora I,Chu H et al. The Lipid Treatment Assessment Project (L - TAP) : a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals[J]. Arch intern Med, 2000,160:459-467.
-
9EUROASPIRE I Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries: principal results results from EUROASPIRE I Euro Heart Survey Programme[J]. Eur Heart 1.2001.22,554- 572.
-
10Tsuyuki RT, Bungard TJ. Poor adherence with hypolipidemic drugs: a lost opportuneity[J]. Pharmacotherpy ,2001,21 : 576- 582.
-
1孟磊.冠心病患者降脂药物的应用评价[J].中国医院用药评价与分析,2004,4(4):207-209. 被引量：12
-
2赵梦华,石建平,田洪森.冠心病高危患者的降脂治疗[J].世界临床药物,2003,24(11):665-668.
-
3方唯一,张双月.家族性高胆固醇血症的调脂治疗[J].辽宁医学杂志,2003,17(2):69-70.
-
4邹大进.贝特类药物的独特调脂作用[J].糖尿病之友,2007(8):46-46.
-
5彭道地,孙明.苯氧芳酸类调血脂药临床应用进展[J].中国医师杂志,2003,5(12):1724-1725. 被引量：1
-
6华琦,师树英,王亭,何士大.苯氧芳酸类血脂调节药物吉非罗齐疗效观察[J].中华内科杂志,1997,36(11):735-735. 被引量：5
-
7姜妮,林金秀,苏津自.贝特类药物的非调脂作用[J].高血压杂志,2005,13(3):134-136. 被引量：7
-
8梁显亮.普罗布考与吉非罗齐降脂作用比较分析[J].广西医学,1999,21(1):61-63.
-
9沈潞华.合理选择降脂药[J].中国全科医学（医生读者版）,2009(10):18-19.
-
10黄萍,陈庆宪,谭荣.重庆市18家医院2004～2006年调脂药应用分析[J].中国药房,2008,19(26):2013-2015. 被引量：3
